Parallax Volatility Advisers, L.P. Cytokinetics Inc Call Options Transaction History

Parallax Volatility Advisers, L.P.

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$51.22 - $60.16 $138,294 - $162,432	-2,700 Reduced 27.0%	7,300 $385,000
Q2 2024 Aug 14, 2024	BUY	$47.86 - $75.05 $320,662 - $502,835	6,700 Added 203.03%	10,000 $541,000
Q1 2024 May 15, 2024	SELL	$63.75 - $108.06 $274,125 - $464,658	-4,300 Reduced 56.58%	3,300 $231,000
Q4 2023 Feb 14, 2024	BUY	$26.88 - $83.49 $204,288 - $634,524	7,600 New	7,600 $634,000
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $178,850 - $255,550	-5,000 Reduced 8.13%	56,500 $2.59 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $2.37 Million - $3.35 Million	61,500 New	61,500 $2.98 Million
Q2 2021 Aug 16, 2021	SELL	$19.79 - $26.99 $773,789 - $1.06 Million	-39,100 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$18.57 - $25.68 $726,087 - $1 Million	39,100 New	39,100 $909,000
Q4 2020 Feb 16, 2021	SELL	$15.26 - $28.61 $59,514 - $111,579	-3,900 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$20.58 - $28.96 $80,262 - $112,944	3,900 New	3,900 $84,000

410

125M

4.6M

2.43M

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.36B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.